Healthcare / Medical DevicesNYSE American
$36.56
+1.03 (+2.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $8.7M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
58/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$303M
P/E
32.2x
↑EV/EBITDA
29.6x
↑ROE
17.4%
↑Gross Margin
78.1%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2011–2025 · 14 años de histórico normalizado
Revenue CAGR
+9.1%
FCF CAGR
—
FCF margin
17.3%
FCF / Net income
1.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $64.0M · net income $7.5M · FCF $11.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||
| Revenue | $64.0M | $64.0M | $54.7M | $48.1M | $41.7M | $35.8M | $32.5M | $31.3M | $28.3M | $25.9M | $23.0M | $19.4M | $15.5M | $15.1M | $19.5M | $19.0M |
| Net Income | $7.5M | $7.5M | $5.2M | $3.2M | $2.3M | $2.4M | $4.2M | $2.0M | $1.8M | $2.2M | $2.2M | $1.1M | $-1.3M | $-1.3M | $186606.00 | $1.1M |
| EBITDA | $10.8M | $10.8M | $7.4M | $4.6M | $3.6M | — | — | — | — | — | — | — | — | — | — | — |
| EPS | 0.85 | 0.85 | 0.58 | 0.36 | 0.26 | 0.27 | 0.47 | 0.23 | 0.21 | 0.26 | 0.27 | 0.13 | -0.16 | — | 0.02 | 0.13 |
| Gross Margin | 78.1% | 78.1% | 76.3% | 76.0% | 75.5% | 76.4% | 77.6% | 76.2% | 76.9% | 79.5% | 77.7% | 70.1% | 68.7% | 69.2% | 72.4% | 72.5% |
| Operating Margin | 15.1% | 15.1% | 12.0% | 8.3% | 7.1% | 8.8% | 15.8% | 9.0% | 9.6% | 13.8% | 13.5% | 6.8% | -4.8% | -12.1% | 3.1% | 9.8% |
| Net Margin | 11.8% | 11.8% | 9.4% | 6.6% | 5.5% | 6.6% | 12.8% | 6.3% | 6.5% | 8.6% | 9.6% | 5.6% | -8.3% | -8.8% | 1.0% | 5.6% |
| Balance Sheet | ||||||||||||||||
| Debt/Equity | — | — | — | — | — | — | — | — | — | 0.06 | 0.07 | 0.09 | 0.10 | 0.10 | 0.09 | 0.11 |
| Current Ratio | 4.91 | 4.91 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||
| Free Cash Flow | $11.1M | $11.1M | $8.7M | $-401000.00 | $-2.2M | $2.8M | $3.4M | $1.3M | $1.9M | $572358.00 | $1.6M | — | — | — | $-2.0M | $-1.9M |
| Returns | ||||||||||||||||
| ROE | 17.4% | 17.4% | 11.6% | 8.4% | 6.7% | 7.3% | 13.8% | 7.7% | 8.1% | 11.2% | 13.5% | 7.8% | -10.1% | -9.5% | 1.2% | 7.2% |
| Valuation | ||||||||||||||||
| P/E | 32.19 | 32.19 | 24.50 | 30.33 | 38.08 | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 29.58 | 29.58 | 14.81 | 18.97 | 21.85 | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 7.77 | 7.77 | 2.83 | 2.52 | 2.54 | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||
| Revenue Growth | 17.0% | 17.0% | 13.8% | 15.4% | — | 10.1% | 3.7% | 10.6% | 9.5% | 12.5% | 18.5% | 25.3% | 2.5% | -22.6% | 2.7% | — |
| EPS Growth | 46.6% | 46.6% | 61.1% | 38.5% | — | -42.6% | 104.3% | 9.5% | -19.2% | -3.7% | 107.7% | 181.3% | — | — | -84.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
56.3%
EPS terminal req.
$3.24
Spread vs growth
-9.7%
5Y implied EPS CAGR
35.8%
EPS terminal req.
$3.93
Spread vs growth
10.8%
10Y implied EPS CAGR
22.2%
EPS terminal req.
$6.32
Spread vs growth
24.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+84.1%
Start / end P/E
35.3x → 44.3x
EPS bridge
0.58 → 0.85
Residual
+11.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.